• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    dievini and the Federal Republic of Germany Amend Shareholders' Agreement Regarding Investments in CureVac N.V.

    1/13/22 4:45:00 PM ET
    $CVAC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CVAC alert in real time by email

    BERLIN, GERMANY / ACCESSWIRE / January 13, 2022 / Today dievini and the Federal Republic of Germany announced the signing of a supplement to the shareholders' agreement between Kreditanstalt für Wiederaufbau (KfW) and the investment company dievini Hopp BioTech holding GmbH & Co. KG (dievini), DH-LT-Investments GmbH, and Dietmar Hopp related to their common shares in CureVac N.V. (CureVac) (NASDAQ:CVAC). The shareholders' agreement was originally signed on 16 June 2020. It governs, among other things, the voting behavior of the shareholders, the appointment of members to the Supervisory Board of CureVac, and certain holding periods and rights of first offer mechanisms for CureVac common shares. Today, both dievini and the KfW made a 13-D filing with the U.S. Securities and Exchange Commission (SEC), which sets out details of the supplement to the shareholders' agreement.

    The supplement to the shareholders' agreement has been agreed because of succession planning for Dietmar Hopp's estate. As part of this succession arrangement, ownership of dievini will be transferred entirely to the Hopp family. The managing co-partners of dievini next to Dietmar Hopp will leave dievini in their current capacity and will, in the course of the separation, directly receive proportional stakes according to their holdings in CureVac and dievini's other portfolio companies as consideration. Notwithstanding this change in the ownership of dievini, the departing managing co-partners will continue to act as managing directors of dievini's general partner and oversee the investments in the portfolio companies.

    In due course and solely to finance the restructuring (including tax obligations for involved parties), dievini intends to sell CureVac common shares. Apart from this, dievini, Dietmar Hopp and his holding company, DH-LT-Investments, as well as the Federal Republic of Germany currently do not plan to sell CureVac common shares to third parties.

    This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.

    About dievini
    dievini Hopp BioTech holding GmbH & Co. KG is a holding company of SAP co-founder Dietmar Hopp with an investment focus on innovative biotechnology companies. dievini holds investments in a total of nine companies in Germany, Switzerland, and Italy, almost all of which are developing diagnostics, therapeutics, and vaccines against serious diseases such as cancer, bacterial and viral infections, and neurodegenerative disorders based on deep clinical-molecular expertise and novel technological approaches. Dietmar Hopp and dievini have been shareholders of CureVac AG, Tübingen, since 2005. Currently, dievini holds approximately 42% of the common shares in CureVac.

    Media Contact dievini
    Katja Arnold, MC Services AG
    Phone: +49 (0)89 210 228 40
    [email protected]

    Media Contact Federal Ministry for Economic Affairs and Climate Action
    Dr. Beate Baron, Press Spokesperson
    Phone: +49 (0)30 18 615 7667
    [email protected]

    SOURCE: dievini Hopp BioTech holding GmbH & Co. KG



    View source version on accesswire.com:
    https://www.accesswire.com/683455/dievini-and-the-Federal-Republic-of-Germany-Amend-Shareholders-Agreement-Regarding-Investments-in-CureVac-NV

    Get the next $CVAC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CVAC

    DatePrice TargetRatingAnalyst
    6/13/2025$5.00Buy → Hold
    Jefferies
    4/25/2024$12.00 → $4.00Outperform → Market Perform
    Leerink Partners
    6/8/2023$13.00Outperform
    SVB Securities
    1/19/2023$8.00 → $18.00Neutral → Buy
    UBS
    1/9/2023$9.00 → $21.00Hold → Buy
    Jefferies
    1/21/2022$55.00 → $20.00Neutral → Underperform
    B of A Securities
    1/18/2022$52.00Market Outperform
    JMP Securities
    10/22/2021$35.00Hold
    Deutsche Bank
    More analyst ratings

    $CVAC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • CureVac downgraded by Jefferies with a new price target

      Jefferies downgraded CureVac from Buy to Hold and set a new price target of $5.00

      6/13/25 7:46:06 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CureVac downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded CureVac from Outperform to Market Perform and set a new price target of $4.00 from $12.00 previously

      4/25/24 7:53:11 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Securities initiated coverage on CureVac with a new price target

      SVB Securities initiated coverage of CureVac with a rating of Outperform and set a new price target of $13.00

      6/8/23 7:45:44 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVAC
    SEC Filings

    See more
    • SEC Form 425 filed by CureVac N.V.

      425 - CureVac N.V. (0001809122) (Subject)

      6/17/25 4:21:12 PM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by CureVac N.V.

      6-K - CureVac N.V. (0001809122) (Filer)

      6/16/25 4:16:56 PM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by CureVac N.V.

      SCHEDULE 13D/A - CureVac N.V. (0001809122) (Subject)

      6/16/25 4:01:02 PM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVAC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer

      Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech's next key milestone in the execution of its oncology strategy Acquisition of CureVac will complement BioNTech's capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturing Public exchange offer for all shares of CureVac where each share of CureVac will be exchanged for approx. $5.46 in BioNTech American Depositary Shares ("ADSs"), representing a premium of 55% to CureVac's three-month volume weighted average price of approx. $3.53 as of June 11, 2025All-stock acquisition has potential to create

      6/12/25 6:45:00 AM ET
      $BNTX
      $CVAC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

      Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter€400 million upfront payment from restructured GSK collaboration reflected in financials, cash position increased to €551 million; expected cash runway re-affirmed into 2028CVGBM Phase 1 glioblastoma study showed 77% of patients with antigen-specific T-cell responses; data presented at ESMO, SITC and SNONew off-the-shelf program for squamous non-small cell lung cancer started, expected to enter Phase 1 in H2 2025New preclinical prophylactic vaccine program for urinary tract infections initiated, supported by positive preclinical data versus protein-based vaccinesPositive Phase 2 data from seasonal influen

      11/12/24 7:20:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

      TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 7, 2024 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the third quarter and first nine months 2024 on Tuesday, November 12, 2024. The company will host a conference call and webcast on the same day at3 p.m. CET / 9 a.m. EST.Dial-in numbers to participate in the conference call:U.S. Toll-Free: +1-877-407-0989International: +1-201-389-0921Germany: 0800-182-0040 (landline access) / 0800-184-4713 (cell phone access)The live webcast link can be accesse

      11/7/24 7:30:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care